Literature DB >> 25858803

The journey from discoveries in fundamental immunology to cancer immunotherapy.

Jacques F A P Miller1, Michel Sadelain2.   

Abstract

Recent advances in cancer immunotherapy have directly built on 50 years of fundamental and technological advances that made checkpoint blockade and T cell engineering possible. In this review, we intend to show that research, not specifically designed to bring relief or cure to any particular disease, can, when creatively exploited, lead to spectacular results in the management of cancer. The discovery of thymus immune function, T cells, and immune surveillance bore the seeds for today's targeted immune interventions and chimeric antigen receptors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25858803     DOI： 10.1016/j.ccell.2015.03.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  76 in total

1.  Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.

Authors:  Ailing Wu; Qingzhe Wu; Yujie Deng; Yuning Liu; Jinqiu Lu; Liansheng Liu; Xiaoling Li; Cheng Liao; Bin Zhao; Hai Song
Journal:  EMBO J       Date:  2018-11-05       Impact factor: 11.598

Review 2.  T cell metabolic reprogramming and plasticity.

Authors:  Maria Slack; Tingting Wang; Ruoning Wang
Journal:  Mol Immunol       Date:  2015-08-12       Impact factor: 4.407

3.  Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.

Authors:  Hongxia Zhang; Xinru You; Xiaojuan Wang; Lei Cui; Zining Wang; Feifei Xu; Mengyun Li; Zhenggang Yang; Jinyun Liu; Peng Huang; Yang Kang; Jun Wu; Xiaojun Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

Review 4.  Leukaemia 'firsts' in cancer research and treatment.

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 5.  Mechanisms of checkpoint inhibition-induced adverse events.

Authors:  P Urwyler; I Earnshaw; M Bermudez; E Perucha; W Wu; S Ryan; L Mcdonald; S N Karagiannis; L S Taams; N Powell; A Cope; S Papa
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

6.  Engineering multicellular systems: using synthetic biology to control tissue self-organization.

Authors:  Marion B Johnson; Alexander R March; Leonardo Morsut
Journal:  Curr Opin Biomed Eng       Date:  2017-12

Review 7.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

8.  Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy.

Authors:  Bongseo Choi; Huijin Jung; Bo Yu; Hyunjun Choi; Joonseok Lee; Dong-Hyun Kim
Journal:  Small       Date:  2019-11-07       Impact factor: 13.281

9.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

Authors:  Zeguo Zhao; Maud Condomines; Sjoukje J C van der Stegen; Fabiana Perna; Christopher C Kloss; Gertrude Gunset; Jason Plotkin; Michel Sadelain
Journal:  Cancer Cell       Date:  2015-10-12       Impact factor: 31.743

Review 10.  The next generation of CRISPR-Cas technologies and applications.

Authors:  Adrian Pickar-Oliver; Charles A Gersbach
Journal:  Nat Rev Mol Cell Biol       Date:  2019-08       Impact factor: 94.444
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.